ACCENT-based web calculators to predict recurrence and overall survival in stage III colon cancer.
暂无分享,去创建一个
Daniel J Sargent | Greg Yothers | Lindsay A Renfro | Chris Twelves | R. Labianca | D. Sargent | C. Loprinzi | A. Grothey | L. Saltz | S. Alberts | C. Allegra | G. Yothers | C. Twelves | L. Renfro | T. André | Roberto Labianca | Axel Grothey | Carmen J Allegra | Thierry André | Charles L Loprinzi | Steven R Alberts | Leonard B Saltz | Yuan Xue | Yuan Xue
[1] J. Hecht,et al. Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. , 2012, The Lancet. Oncology.
[2] N. Petrelli,et al. Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] R Core Team,et al. R: A language and environment for statistical computing. , 2014 .
[4] S. Cha,et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] M Buyse,et al. Two or three year disease-free survival (DFS) as a primary end-point in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07 and C89803. , 2011, European journal of cancer.
[6] P. Grambsch,et al. Proportional hazards tests and diagnostics based on weighted residuals , 1994 .
[7] E. Steyerberg. Clinical Prediction Models , 2008, Statistics for Biology and Health.
[8] T. Hickish,et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] Roderick J. A. Little,et al. Statistical Analysis with Missing Data: Little/Statistical Analysis with Missing Data , 2002 .
[10] E. Van Cutsem,et al. Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] C. Compton,et al. AJCC Cancer Staging Manual , 2002, Springer New York.
[12] T. Hickish,et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. , 2004, The New England journal of medicine.
[13] Mithat Gonen,et al. Individualized prediction of colon cancer recurrence using a nomogram. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] N. Petrelli,et al. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] Mithat Gönen,et al. Predicting survival after curative colectomy for cancer: individualizing colon cancer staging. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] D. Sargent,et al. Adjuvant mFOLFOX6 with or without cetuxiumab (Cmab) in KRAS wild-type (WT) patients (pts) with resected stage III colon cancer (CC): Results from NCCTG Intergroup Phase III Trial N0147. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] Daniel J Sargent,et al. Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] D. Sargent,et al. Mining the ACCENT database: a review and update. , 2013, Chinese clinical oncology.
[19] J. Taieb,et al. Cetuximab plus FOLFOX-4 for fully resected stage III colon carcinoma: scientific background and the ongoing PETACC-8 trial , 2008, Expert review of anticancer therapy.
[20] D. Sargent,et al. Prognostic web‐based models for stage II and III colon cancer , 2011, Cancer.
[21] Martha Sajatovic,et al. Clinical Prediction Models , 2013 .
[22] Nicole A. Lazar,et al. Statistical Analysis With Missing Data , 2003, Technometrics.